
NASDAQHealthcareMedical - Devices
Latest quote
$94.72
+$0.48 · +0.51%
iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with BioIS to develop and commercialize pulse oximetry, accelerometry, and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring products and services. The company was formerly known as iRhythm Technologies, Inc. and changed its name to iRhythm Holdings, Inc. in January 2026. iRhythm Holdings, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Previous close
$94.72
+$0.48 · +0.51%
Regular session · ET · Market data may be delayed.
iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with BioIS to develop and commercialize pulse oximetry, accelerometry, and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring products and services. The company was formerly known as iRhythm Technologies, Inc. and changed its name to iRhythm Holdings, Inc. in January 2026. iRhythm Holdings, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Day range
Current $94.72
52-week range
Current $94.72
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
78
Undervalued
Sentiment
66
Bullish
Risk
59
Elevated Risk
Momentum
34
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with BioIS to develop and commercialize pulse oximetry, accelerometry, and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring products and services. The company was formerly known as iRhythm Technologies, Inc. and changed its name to iRhythm Holdings, Inc. in January 2026. iRhythm Holdings, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Day range
Current $94.72
52-week range
Current $94.72
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 747.14M USD | 591.84M USD | 492.68M USD | 410.92M USD | 322.83M USD |
| Cost of goods sold | 219.89M USD | 184.31M USD | 160.88M USD | 129.29M USD | 109.26M USD |
| Gross profit | 527.25M USD | 407.53M USD | 331.81M USD | 281.63M USD | 213.57M USD |
| Research and development | 84.61M USD | 103.83M USD | 60.24M USD | 46.61M USD | 38.67M USD |
| Selling, general, and administrative | 479.45M USD | 418.57M USD | 385.65M USD | 322.2M USD | 274.84M USD |
| Operating expenses | 564.06M USD | 523.04M USD | 456.97M USD | 395.42M USD | 313.51M USD |
| Interest income | 21.52M USD | 21.94M USD | 6.16M USD | 2.35M USD | 118K USD |
| Interest expense | 13.15M USD | 12.82M USD | 3.65M USD | 4.14M USD | 1.17M USD |
| Depreciation and amortization | 26.48M USD | 25.78M USD | 22.14M USD | 19.61M USD | 16.59M USD |
| Operating income | −36.81M USD | −115.51M USD | −125.16M USD | −113.78M USD | −99.94M USD |
| Net income | −44.55M USD | −113.29M USD | −123.41M USD | −116.16M USD | −101.36M USD |
Company facts updated Nov 22, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$169.63
79.09% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI99.96M0.01%689.3B USD0.03%$340.02-3.52%
Vanguard Morningstar Small-Cap ETFVB89.41M0.05%78.7B USD0.03%$270.68-2.56%
iShares Russell 2000 ETFIWM84.03M0.12%71.54B USD0.19%$256.61-2.88%
Vanguard Morningstar Small-Cap Growth ETFVBK50.05M0.12%22.5B USD0.05%$298.35-3.85%
Vanguard Extended Market ETFVXF46.21M0.05%30.2B USD0.05%$211.44-3.21%
iShares Russell 2000 Growth ETFIWO29.46M0.22%12.73B USD0.24%$320.43-3.57%
Vanguard Russell 2000 ETFVTWO24.03M0.13%16.8B USD0.06%$103.76-2.76%
Schwab U.S. Small-Cap ETFSCHA16.2M0.08%20.45B USD0.03%$30.51-2.83%
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Morningstar Small-Cap ETFVB
iShares Russell 2000 ETFIWM
Vanguard Morningstar Small-Cap Growth ETFVBK
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
Vanguard Russell 2000 ETFVTWO
Schwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.